0.035
0.00 (-10.26%)
| Previous Close | 0.039 |
| Open | 0.040 |
| Volume | 1,653,205 |
| Avg. Volume (3M) | 863,488 |
| Market Cap | 80,016,304 |
| Price / Sales | 6.03 |
| Price / Book | 3.78 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 |
| Profit Margin | -183.82% |
| Operating Margin (TTM) | -192.74% |
| Diluted EPS (TTM) | -0.010 |
| Quarterly Revenue Growth (YOY) | 25.60% |
| Total Debt/Equity (MRQ) | 3.24% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -18.29 M |
| Levered Free Cash Flow (TTM) | -14.22 M |
| Return on Assets (TTM) | -29.71% |
| Return on Equity (TTM) | -50.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (AU) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | IMPEDIMED FPO [IPD] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.50 |
|
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 9.29% |
| % Held by Institutions | 16.26% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |